International Symposium on Late Complications After Childhood Cancer

Thursday, June 15 - Saturday, June 17, 2023
Emory Convention Center Hotel, Atlanta, GA, USA

Symposium Overview

In 2022 the North American Symposium on Late Complications After Childhood Cancer (NASLCCC) and the European Symposium on Late Complications After Childhood Cancer (ESLCCC) merged efforts to provide an international forum for survivorship clinicians and researchers.

The newly branded International Symposium on Late Complications After Childhood Cancer (ISLCCC) aims to feature emerging research results and insights from real world clinical experience to promote research collaborations and improve survivorship care throughout the world. The symposium provides a venue for the multidisciplinary exchange of innovative ideas among clinicians and researchers engaged in pediatric cancer survivorship clinical care and/or research. The symposium historically includes global participation of approximately 300 attendees from Europe, Asia, Oceania, South America, Canada, and the United States and will be of interest to oncologists, psychologists, social workers, and survivorship clinicians and researchers. The 2023 ISLCCC will be an in-person event.  For registrants to the symposium, web-based access to recorded sessions will be provided after the meeting.

 

Conference Program

  1. Thursday, June 15
    3:00 pm – 3:15 pm

    Welcome
    Melissa Hudson, St. Jude Children's Research Hospital

    Introduction of Keynote Speaker
    Greg Armstrong, St. Jude Children's Research Hospital
    3:15 – 3:45 pm Keynote
    Leveraging Survivorship Advocacy to Advance Research, Care and Policy
    Diana Merino Vega, PhD, AstraZenica, Gaithersburg, MD
    J.G. (Jaap) den Hartogh, Dutch Childhood Cancer Parent Organization, Nieuwegein, The Netherlands
    3:45–4:30 pm Oral Session #1
    Cardiovascular Disease
    Helena van der Pal
    Ksenya Shliakhsitsava
    3:45–3:55 pm O-Abstract #1
    Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: results from COG ALTE1621
    Saro Armenian
    City of Hope, Duarte, California
    3:55–4:05 pm O-Abstract #2
    Cumulative burden of cardiovascular morbidity in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study
    Rawan Hammoud
    St. Jude Children’s Research Hospital, Memphis, Tennessee
    4:05–4:15 pm O-Abstract #3
    Enhancing prediction of therapy-related cardiomyopathy from surveillance echocardiograms: a Children’s Oncology Group report
    Eric Chow
    Seattle Children’s Hospital, Seattle, Washington
    4:15–4:30 pm Panel Discussion
    4:30–5:25 pm Abstract Theme #2
    Cardiovascular Disease and Risk Factors
    Elvira van Dalen
    Stephanie Dixon
    4:30–4:40 pm O-Abstract #4
    Influence of genetic predisposition and lifestyle on modifiable  cardiovascular risk factors among survivors of childhood cancer
    Carmen Wilson
    St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
    4:40–4:50 pm O-Abstract #5
    Incidence, risk factors, and clinical characteristics of cerebrovascular events among childhood cancer survivors treated with upper body  radiotherapy in the DCCSS-LATER cohort
    Jop Teepen
    Princess Máxima Center, Utrecht, The Netherlands
    4:50–5:00 pm O-Abstract #6
    Prevalence and determinants of dyslipidemia in a national cohort of 2,338 Dutch childhood cancer survivors: a DCCSS-LATER Study
    Melissa Bolier
    Erasmus Medical Center, Rotterdam, The Netherlands
    5:00–5:10 pm O-Abstract #7
    Genetic study of diabetes mellitus risk in diverse populations of survivors of childhood cancer: a report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS)
    Yadav Sapkota
    St. Jude Children’s Research Hospital, Memphis, Tennessee
    5:10–5:25 pm Panel Discussion
    5:30–6:00 pm St. Jude Survivorship Portal on the Cloud Demonstration
    6:00–6:30 pm Break
    6:30–8:00 pm Conference Reception
    Location: Silverbell Pavilion
    7:00 – 9:00 pm Dinner Buffet open
    Location: Garden Level Dining Room
  2. Friday, June 16
    7:15 – 9:00 am Dan Green Fun Run - Meet in the lobby
    6:30 – 9:00 am Breakfast buffet
    Location: Garden Level Dining Room
    9:00 - 9:15 am Welcome back/Introduction of Keynote Speaker
    Leontien Kremer
    9:15–9:45 am Keynote
    Defining Pediatric Cancer Therapy Dose-Tolerances: Findings from the Pediatric Normal Tissue Effects in Clinic (PENTEC) Consortia
    Louis (Sandy) Constine
    University of Rochester Medical Center, Rochester, New York
    9:45 – 10:30 am Abstract Theme #3:
    Breast Cancer
    Flora van Leeuwen
    Jop Teepen
    9:45–9:55 am O-Abstract #8
    Risk of subsequent breast cancer associated with chest radiation field and dose among female childhood cancer survivors: a report from the International Consortium for Pooled Studies on Subsequent Malignancies
    Yuehan Wang
    Princess Máxima Center, Utrecht, Netherlands
    9:55–10:05 am O-Abstract #9
    Treatment and treatment-related toxicity following subsequent breast cancer: a report from the Childhood Cancer Survivor Study (CCSS)
    Cindy Im
    University of Minnesota, Minneapolis Minnesota
    10:05–10:15 am O-Abstract #10
    Predicting breast cancer risk among Hodgkin lymphoma survivors using radiotherapy dose distributions: a report from the Dutch Hodgkin Lymphoma Survivor Study and the Childhood Cancer Survivor Study
    Sander Roberti
    The Netherlands Cancer Institute, Amsterdam (Dutch HL Survivor Study, CCSS)
    10:15–10:30 am Panel Discussion
    10:30 – 10:50 am Refreshment Break
    10:50–11:00 am Intro Clinical Conundrum:
    What is the added value of dual imaging for breast cancer surveillance among at risk female cancer survivors?
    11:00–11:20 am Speaking for dual imaging
    Kevin Oeffinger, MD
    Duke University, Durham, North Carolina
    11:20–11:40 am Speaking against dual imaging
    John Wong, MD
    Tufts University Medical Center, Boston, Massachusetts
    11:40 am–12:00 pm Group Discussion
    Led by Lisa Diller and Yuehan Wang
    12:00 - 1:30 pm Lunch Buffet
    Garden Level Dining Room
    1:30 – 2:15 pm  Abstract Theme #4
    Subsequent Neoplasms
    Lars HJorth
    James Bates
    1:30–1:40 pm O-Abstract #11
    Cumulative absolute risk of subsequent colorectal cancer after abdominopelvic radiotherapy among 69,460 childhood cancer survivors using a clinically accessible metric: a PanCareSurFup Study
    Emma Plant
    University of Birmingham, Birmingham, United Kingdom
    1:40–1:50 pm O-Abstract #12
    Subsequent meningiomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS)
    Lucie Turcotte
    University of Minnesota, Minneapolis, Minnesota
    1:50–2:00 pm O-Abstract #13
    Long-term risk of subsequent malignant and benign neoplasms after childhood neuroblastoma: A DCCSSLATER 3 Study
    Aimee Westerveld
    Princess Máxima Center, Utrecht, The Netherlands
    2:00–2:15 pm Panel Discussion
    2:15–3:00 pm Abstract Theme #5
    Reproductive Outcomes
    Jeanette Winther
    Brooke Cherven
    2:15–2:25 pm O-Abstract #14
    Complications during pregnancy and delivery among female  childhood cancer survivors
    Tina Gerbek
    The Danish Cancer Society, København, Denmark
    2:25–2:35 pm O-Abstract #15
    Delivery rates and obstetric complications in female teenage and young adult cancer survivors: The Teenage and Young Adult Cancer Survivor Study (TYACSS) cohort
    Ceren Sunguc
    University of Birmingham, Birmingham, United Kingdom
    2:35–2:45 pm O-Abstract #16
    GWAS on gonadotoxicity in female childhood cancer survivors: results from the PanCareLIFE study
    Madeleine van der Perk
    Princess Máxima Center, Utrecht, Netherlands
    2:45–3:00 pm Panel Discussion
    3:00–3:30 pm Refreshment Break
    3:30–4:15 pm Abstract Theme #6
    General Survivorship
    Lillian Meacham
    AnnaLynn Williams
    3:30–3:40 pm O-Abstract #17
    Adult growth hormone deficiency, replacement therapy, IGF-1 levels, and chronic health conditions among childhood cancer survivors: a report from the St. Jude Lifetime Cohort (SJLIFE) study
    Tomoko Yoshida
    St. Jude Children's Research Hospital, Memphis, Tennessee
    3:40–3:50 pm O-Abstract #18
    Frailty and sarcopenia within the earliest national Dutch childhood cancer survivor cohort (DCCSS-LATER): a cross-sectional study
    Demi de Winter
    Princess Máxima Center, Utrecht, The Netherlands
    3:50–4:00 pm O-Abstract #19
    Excess risks of antidepressant and antipsychotic medication prescriptions experienced by over 20,000 English childhood cancer survivors
    Emma Plant
    University of Birmingham, Birmingham, United Kingdom
    4:00–4:15 pm Panel Discussion
      Abstract Theme #7
    General Survivorship
    Sharon Castellino
    Ismay Beijer
    4:15–4:25 pm O-Abstract #20
    Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS)
    Andrew Murphy
    St. Jude Children's Research Hospital, Memphis, Tennessee
    4:25–4:35 pm O-Abstract #21
    HPV vaccine initiation in a contemporary multi-site cohort of childhood cancer survivors
    Wendy Landier
    Emory University School of Medicine, Atlanta, Georgia
    4:45–4:55 pm O-Abstract #23
    A core outcome set to measure quality of care for childhood cancer - a joint international consensus statement from the international childhood cancer outcome project
    Rebecca van Kalsbeek
    Princess Máxima Center, Utrecht, The Netherlands
    4:55–5:10 pm Panel Discussion
    5:10–5:12 pm Rapid Poster Preview Introduction
    Eric Chow
    Selina van den Oever
    5:12–5:14 pm P-Abstract #1
    Updated colorectal radiation therapy (RT) dosimetry for the Childhood Cancer Survivor Study (CCSS) cohort
    Constance Owens
    The UT MD Anderson Cancer Center, Houston, Texas 
    5:14–5:16 pm P-Abstract #2
    Subsequent CNS malignancy among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS)
    Robert Galvin
    University of Minnesota, Minneapolis, Minnesota
    5:16–5:18 pm P-Abstract #3
    Persistent variations in blood DNA methylation are associated with skeletal muscle health deficits in adult survivors of childhood cancer
    Chelsea Goodenough
    St. Jude Children's Research Hospital
    5:18–5:20 pm P-Abstract #4
    Triggering, maintaining and moderating factors for cancer-related fatigue in childhood cancer survivors: a DCCSS LATER study
    Adriaan Penson
    Radboud University Medical Center, Nijmegen, The Netherlands 
    5:20–5:22 pm P-Abstract #5
    The role of TTN and BAG3 in therapy-related cardiomyopathy among longterm survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor Study (CCSS)
    Achal Neupane
    St. Jude Children's Research Hospital
    5:22–5:24 pm P-Abstract #6
    Injury-related late mortality among survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS)
    Margaret Lubas
    Radford University, Radford, Virginia
    5:24–5:26 pm P-Abstract #7
    Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: Recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization Group
    Selina van den Oever
    Princess Máxima Center, Utrecht, The Netherlands
    5:26–5:28 pm P-Abstract #8
    Use of prescription drugs in Danish and Swedish childhood cancer survivors – a population-based cohort study from the SALiCCS research program
    Jeanette Winther
    Danish Cancer Society Research Center, Copenhagen, Denmark
    5:28–5:30 pm P-Abstract #9
    Aerobic exercise in children with medulloblastoma during radiation therapy improves cardiopulmonary fitness
    Robyn Partin
    St. Jude Children's Research Hospital
    5:30–5:32 pm P-Abstract #10
    Electronic medical record - embedded clinical and research survivorship database: a single institution experience
    Ksenya Shliakhtsitsava
    University of Texas Southwestern, Dallas, Texas
    5:32–5:34 pm P-Abstract #11
    Retention of vaccine-mediated humoral immunity in survivors of childhood cancer
    Smita Dandekar
    Penn State Children’s Hospital, Hershey, Pennsylvania
    5:34–5:36 pm P-Abstract #12
    Engage: a new childhood cancer survivorship care program
    Jordana McLoone
    University of New South Wales, Sydney, Australia
    5:36–5:38 pm A multisite longitudinal study of engagement of care and self-management of adolescent and young adult survivors of childhood cancer: description of protocol, cohort, and retention
    Lisa Schwartz
    Children’s Hospital of Philadelpia, Philadelphia, Pennsylvania
    5:38–5:40 pm P-Abstract #14
    Work performance and quality of life (QOL) among adolescent and young adult (AYA) cancer survivors
    Neel Bhatt
    Fred Hutchinson Cancer Center, Seattle, Washington
    5:40–6:30 pm Free Time
    6:30 – 8:30 pm Poster Exhibition
    Location: Starvine/Peachtree Creek (Nonaccredited Session)
    7:00 – 9:00 pm Dinner Buffet
    Location: Garden Level Dining Room
    7:30–9:30 pm Social time with colleagues
    Bowling and Pool in Wisteria Lanes
    Relaxing on the patio
  3. Saturday, June 17
    6:30-9:00 am Breakfast Buffet
    Location: Garden Level Dining Room
    8:00 – 8:15 am Welcome back/ Introduction of Keynote Speaker #3
    Greg Armstrong
    St. Jude Children's Research Hospital
    8:15–8:45 am Keynote
    Immunotherapy in Children with Cancer: Why is Long-Term Follow-Up Important?
    David Teachey, MD
    Children’s Hospital of Philadelphia, Pennsylvania
    8:45–9:40 am Abstract Theme #8
    Genetics/Genomics
    Smita Bhatia
    Eline Bertrums
    8:45–8:55 am O-Abstract #24
    A genome-wide association study for doxorubicin-induced cardiomyopathy in childhood cancer survivors from the St. Jude Lifetime Cohort (SJLIFE) and the Childhood Cancer Survivor (CCSS) Studies
    Kateryna Petrykey
    St. Jude Children's Research Hospital
    8:55–9:05 am O-Abstract #25
    Polygenic risk of anthracycline-related cardiomyopathy in childhood cancer survivors: report from Children’s Oncology Group and Childhood Cancer Survivor Study (CCSS)
    Noha Sharafeldin
    University of Alabama at Birmingham, Birmingham, Alabama
    9:05–9:15 am O-Abstract #26
    Cancer predisposition variants and late-mortality from subsequent malignant neoplasms among long-term survivors of childhood cancer: a report from the St. Jude Lifetime Cohort and the  Childhood Cancer Survivor Study (CCSS)
    Cheng Chen
    St. Jude Children's Research Hospital
    9:15–9:25 am O-Abstract #27
    Clonal hematopoiesis in childhood cancer survivors
    Kelly Bolton
    Memorial Sloan Kettering Cancer Center, New York, New York
    9:25–9:40 am Panel Discussion
    9:40–10:35 am Abstract Theme #9
    Aging
    Kevin Krull
    Saskia Pluijm
    9:40–9:50 am O-Abstract #28
    Associations between psychosocial and lifestyle factors and biological age acceleration among long-term survivors of childhood cancer: a prospective study
    Brennan Streck
    National Cancer Institute, Rockville, Maryland
    9:50–10:00 am O-Abstract #29
    Treatment associated brainchronologic age difference and neurocognitive outcomes in adult childhood cancer survivors.
    Nicholas Phillips
    St. Jude Children's Research Hospital
    10:00–10:10 am O-Abstract #30
    Racial disparity in epigenetic age acceleration among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort
    Noel-Marie Plonski
    St. Jude Children's Research Hospital
    10:10–10:20 am O-Abstract #31
    Mortality and the burden of subsequent malignant neoplasms in survivors of childhood cancer beyond age 50: a report from the Childhood Cancer Survivor Study (CCSS)
    Rusha Bhandari
    City of Hope Medical Center, Duarte, California
    10:20–10:35 am Panel Discussion
    10:35–11:00 am Refreshment Break
    11:00–11:55 am Abstract Theme #10
    Late Onset Morbidity
    Paul Nathan
    Kayla Foster
    11:00–11:10 am O-Abstract #32
    A multicenter cooperative group study of late effects after high-risk neuroblastoma (COG ALTE15N2/late effects after high-risk neuroblastoma (LEAHRN) study)
    Tara Henderson
    University of Chicago, Chicago, Illinois
    11:10–11:20 am O-Abstract #33
    Long-term outcomes of adolescents and young adults with testicular germ cell tumors: a population-based retrospective matched cohort study
    Rand Ajaj
    The Hospital for Sick Children, Toronto, Ontario, Canada
    11:20–11:30 am O-Abstract #34
    A phase IV trial of proton therapy in children: the first report from the SJPROTON1 Study
    John Lucas
    St. Jude Children's Research Hospital
    11:30–11:40 am O-Abstract #35
    Clinico-molecular correlates of quality of survival and neurocognitive outcomes in medulloblastoma; a metaanalysis of the SIOP-UKCCSGPNET3 and HIT-SIOP-PNET4 trials
    Debbie Hicks
    Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom
    11:40–11:55 am Panel Discussion
    11:55 am–12:00 pm Closing/Save the Date ISLCCC 2024
    Melissa Hudson
 

Registration

Registration will open January 13, 2023.  A discount is offered for registrations received on or before Monday, April 17, 2023, at 11:59 PM CST.

Registration will be securely processed online only and will be confirmed immediately by email. Below you will find information related to registration fees, special rate categories, registration changes, and cancellations. Due to limited space, early registration is encouraged.

Registrations received by April 17, 2023, are:

  • Physicians or Professors: $575
  • Non-physicians (PhDs, Fellows, NPs, Nurses): $525
  • Students or Survivors: $400

Registrations received after April 17, 2023, are:

  • Physicians or professors: $625
  • Non-physicians (PhDs, Fellows, NPs, Nurses): $575
  • Students or Survivors: $400

Fees are payable at the time of registration and include access to all Symposium educational and scientific sessions, program book, and poster sessions and web-based access to the recorded sessions after the meeting, as well as Continuing Medical Education (CME) for physicians and Nursing Continuing Professional Development (NCPD) credits for nurses. Visa, MasterCard, Discover, and American Express are accepted for payment. Registrations will not be processed without full payment.

In addition to the above, your registration will include the following at the Emory Conference Center Hotel:

  • Welcome Reception on Thursday evening
  • Breakfast on Friday and Saturday
  • Lunch on Friday
  • Dinner on Thursday and Friday

Refund Policy: Cancellations may be made using the link in your ISLCCC registration confirmation or a transfer of registration to a colleague may be requested by the original registrant with the link. Any requests for cancellations or changes must be submitted no later than May 10, 2023. An administration fee of $50 will be assessed for any cancellations and no refunds will be granted after May 10, 2023.

  1. Emory Conference Center Hotel
    1615 Clifton Road NE
    Atlanta, Georgia 30329 US
    Phone: 404-712-6000

    Each attendee is responsible for securing their hotel reservation at the Emory Conference Center Hotel. The hotel conference rate will expire on Tuesday, May 23, 2023. After that date, you may be able to obtain a room but it will be at the Emory Conference Center Hotel’s current published rate. Make your reservations early as the room block will fill quickly!

    Double Occupancy room rates may be split by calling the hotel directly to make reservations. Be sure to reference the conference code ISLCCC.

    Emory Conference Center Hotel Room Rate:

    • $180 nightly for Single or Double  Occupancy

    Book a Hotel Room

  2. Abstract Submissions will open on January 13, 2023. The submission deadline is February 27, 2023, 11:59 pm CST.
    Participants are invited to submit abstracts for review.  Abstracts will be accepted only through the conference website and there is no fee for submission.  Abstracts will be reviewed by the Program Committee for selection of Oral and Poster presentations and accepted abstracts will be published in the ISLCCC Program Book.

    Acceptance notifications and guidelines for presentation will be sent in April 2023. Authors of accepted abstracts who have not registered for the Symposium will have until April 17, 2023, to do so at the discounted registration rate (early registration is highly recommended).

    Please note that submitting an abstract does not register you for the meeting.

    Abstract Guidelines

    • There is no limit to the number of abstracts an individual may author.
    • Abstracts must be written in English.
    • Abstracts are limited to 3,000 characters, including spaces.
    • Use a concise title.
    • List affiliations of author(s) as briefly as possible with name, degree, hospital, city, state, country.
    • Use standard and well-accepted abbreviations.
    • One table or graphic may be inserted in a .jpg format only.
    • Abstract content should be single spaced, typed in sentence case and contain:
      • Background/Purpose
      • Methods
      • Results
      • Conclusions

    Abstract Categories

    Abstracts can be submitted in the following categories (please indicate category desired in submission):

    • Late effects including subsequent neoplasms and mortality
    • Research Methods/Epidemiology
    • Health Services Research
    • Intervention Research
    • Survivorship Care Planning
    • Survivorship Health Screening Guidelines
    • Genetics/Genomics

    Submit an Abstract

  3. Childhood Cancer Survivorship Study (CCSS) Investigator Meeting

    The CCSS Investigator Meeting will convene June 14-15, 2023, at the Emory Conference Center Hotel preceding the International Symposium on Late Complications After Childhood Cancer.  The Investigator Meeting is open to anyone who wants to attend. The Plenary Session will begin at 2:00 pm on Wednesday, June 14, following the morning Executive Committee and Steering Committee Meetings and end on June 15 at 12:00 PM.   A detailed CCSS Investigator Meeting Agenda as well as details on conference center location and accommodations will be provided in on the CCSS website as soon as they are available: https://ccss.stjude.org/investigator-meetings. Until then, please hold these dates on your calendar in anticipation of this event.

    International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG)

    Participants in the IGHG will meet on June 15, 2023, from 12:00 PM - 2:30 PM (following the conclusion of the CCSS Investigator Meeting). A detailed meeting agenda and conference center location will be provided in early 2023. IGHG expert panel members and individuals interested in participating IGHG initiatives are welcome to attend. A detailed IGHG meeting agenda as well as information about the conference center location will be provided in early 2023 and posted at www.ighg.org.

    Dan Green Fun Run: Local program committee members are planning an event for Friday morning, June 16, 2023, and details will be forthcoming. 

  4. Major Airports

    The nearest major airport to The Emory Conference Center Hotel is the Atlanta Hartsfield International Airport.

    Ground Transportation

    Taxi service, Lyft, and Uber, and various shuttle services are all available from the Atlanta Hartsfield International Airport.

  5. Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of St. Jude Children’s Research Hospital and the Princess Maxima Center for Pediatric Oncology. St. Jude Children’s Research Hospital is accredited by the ACCME to provide continuing medical education for physicians.

    St. Jude Children’s Research Hospital is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

    Objectives

    As a result of participating in this educational program, participants should be able to:

    • Describe common long-term physical and emotional sequelae of childhood cancer
    • Implement appropriate interventions to prevent, remediate, or promote early detection of cancer-/treatment-related medical and psychosocial complications in childhood cancer survivors
    • Recognize challenges in delivery of high quality survivorship care
    • Identify emerging signals of late toxicity associated with novel cancer treatment strategies
 
 

Register

Close
Close